Roche faces UK pricing row over multiple sclerosis drug Ocrevus

roche faces uk pricing row over multiple sclerosis drug ocrevus

Roche faces a fresh row over drug pricing in Britain, following a decision by the body responsible for medicine use within the state health service not to approve its drug Ocrevus for treating a highly disabling form of multiple sclerosis (MS).

Roche faces UK pricing row over multiple sclerosis drug Ocrevus Roche faces UK pricing row over multiple sclerosis drug Ocrevus Roche faces UK pricing row over multiple sclerosis drug Ocrevus

Roche faces UK pricing row over multiple sclerosis drug Ocrevus Read Entire Article On Reuters

Author: HEDGE

Hedge Accordingly was founded ahead of the global financial crisis in January of 2008, with the goal of providing our readers our unique take on The Latest News on Wall Street, Stocks, #Politics and Business news. Hedge Accordingly produces both original, and aggregated #Wallst news content from top publishers around the world. We curate aggregated content covering the latest news on politics, stocks, wall street, and the tech industry. We also provide free stock charting, quotes and a bitcoin, forex and currency exchange. Learn More About HEDGEaccordingly.com